Trump's 25% Drug Tariff Ceiling: Which Indian Pharma Giants Have the Most to Lose
The Trump administration's latest drug import order, setting a 25% tariff ceiling on pharmaceutical imports, has sent shockwaves through India's pharma sector. India supplies over 40% of America's generic drugs, and the country's biggest pharma companies have spent years building billion-dollar US businesses. Now, their own filings reveal just how exposed they are.
The stakes are enormous
As Sigachi Industries noted in its FY25 annual report: "Proposed tariffs, potentially set at 25% or higher, could result in billions of dollars in additional costs, consequently raising generic prices for consumers in the United States." Sun Pharma Advanced Research's (SPARC) annual report was blunter: the return of "aggressive US industrial and trade protectionism" with "tariff measures targeting imported pharmaceuticals and APIs created significant uncertainty for global supply chains."
Pfizer India's annual report added that "the US Government's reciprocal tariff policy is likely to significantly impact Indian pharmaceutical companies, particularly those exporting to the US market."
These aren't analyst guesses — they're risk disclosures from companies that know their own exposure.
Ranking the exposure: Who earns the most from America
Lupin is the most exposed of India's major pharma companies. Per its Q1 FY27 investor presentation, the United States accounted for INR 34,348 million — a striking 42% of its total revenue of INR 82,172 million. This US dependence has been growing: it was 44% in Q3 FY26 and 46% in Q4 FY26. The company is the largest generic company in the US by prescriptions. Sun Pharma reported US revenue of INR 176,199 million out of INR 582,201 million total in FY26, making the US roughly 30% of its consolidated revenue. Its specialty brand Innovative Medicines crossed $1 billion in US sales for the first time during the year. The company also took a US restructuring charge of $11.7 million in Q4 FY25. Cipla earned $934 million from North America in FY26 — its highest ever — making the US about 24% of total revenue of INR 28,163 crores. The company has shipped over 50 million albuterol inhalers to the United States over the past five years. Dr. Reddy's is annualizing roughly $950 million in North America revenue, per its earnings call. But the company is already feeling pressure: Q1 FY27 revenue declined 6% year-on-year, and management flagged "significant price erosion" in the US base business over the past four years despite launching 90 to 100 new products.The margin squeeze math
A 25% tariff on a business already battling price erosion could be devastating. Consider the margin buffers these companies are working with:
- Sun Pharma: FY25 EBITDA margin of 29.0% with a gross margin of 79.3% — the strongest cushion in the group
- Lupin: H1 FY26 EBITDA margin improved to 29.1% from 23.6% a year earlier, with gross margins at 72.3%
- Dr. Reddy's: Q4 FY25 EBITDA margin of 29.1%, but Q3 FY26 slipped to 23.5% — a 401 basis point year-on-year drop
- Cipla: EBITDA margin around 26% based on recent quarterly results
One company is already in the room
Lupin appears to be ahead of the curve. In its earnings call, management revealed it is "actively exploring" US manufacturing with the National Security Council: "The government has identified 9 drugs that they believe are essential and we go into the dialogue back and forth with them to determine how we can build the partnership between India and the US to give them the confidence that they will have reliability of supply."
Lupin already has manufacturing capacity at Coral Springs and Somerset in the US, and is investing in Ellipta and Respimat inhalation lines — investments that were "already under way even before this administration." Companies with existing US manufacturing will have an easier path to tariff mitigation than those shipping everything from India.
What retail investors should do
Don't panic-sell pharma, but do understand your exposure. If you hold Lupin, know that 42% of its revenue faces tariff risk — but also that the company is uniquely positioned to pivot with existing US plants. Sun Pharma's specialty business and 79% gross margin provide the best buffer. Dr. Reddy's, already battling US price erosion, faces a compounding headwind. Watch for two signals in the coming quarters: which companies announce US manufacturing expansions (bullish) and which report margin compression in their North America segments (bearish). The final tariff rate and any pharma-specific exemptions will determine whether this is a speed bump or a structural reset for India's $30-billion pharma export machine.
Data sourced from company filings on NSE via Xaro.